Kiniksa Pharmaceuticals International, plc $KNSA Holdings Raised by Rhumbline Advisers

Rhumbline Advisers lifted its position in shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) by 6.4% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 62,700 shares of the company’s stock after acquiring an additional 3,745 shares during the period. Rhumbline Advisers owned about 0.09% of Kiniksa Pharmaceuticals International worth $1,393,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in the business. GAMMA Investing LLC increased its stake in Kiniksa Pharmaceuticals International by 84.8% during the first quarter. GAMMA Investing LLC now owns 1,238 shares of the company’s stock valued at $27,000 after purchasing an additional 568 shares during the last quarter. US Bancorp DE bought a new stake in shares of Kiniksa Pharmaceuticals International during the 1st quarter valued at about $33,000. Asset Management One Co. Ltd. acquired a new stake in Kiniksa Pharmaceuticals International during the first quarter worth about $41,000. Wealthquest Corp acquired a new stake in Kiniksa Pharmaceuticals International during the first quarter worth about $42,000. Finally, Lazard Asset Management LLC bought a new position in Kiniksa Pharmaceuticals International in the fourth quarter worth about $61,000. Institutional investors and hedge funds own 53.95% of the company’s stock.

Insiders Place Their Bets

In other Kiniksa Pharmaceuticals International news, CAO Michael R. Megna sold 11,000 shares of Kiniksa Pharmaceuticals International stock in a transaction dated Wednesday, September 3rd. The stock was sold at an average price of $34.84, for a total transaction of $383,240.00. Following the transaction, the chief accounting officer owned 38,011 shares of the company’s stock, valued at $1,324,303.24. The trade was a 22.44% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Thomas Malley sold 78,233 shares of the stock in a transaction that occurred on Thursday, August 14th. The stock was sold at an average price of $33.09, for a total transaction of $2,588,729.97. Following the completion of the sale, the director directly owned 12,546 shares of the company’s stock, valued at $415,147.14. This trade represents a 86.18% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 561,371 shares of company stock worth $18,825,009. 53.48% of the stock is currently owned by corporate insiders.

Kiniksa Pharmaceuticals International Price Performance

Kiniksa Pharmaceuticals International stock opened at $35.42 on Friday. Kiniksa Pharmaceuticals International, plc has a fifty-two week low of $17.82 and a fifty-two week high of $37.34. The firm’s 50 day simple moving average is $32.62 and its 200-day simple moving average is $27.61. The company has a market cap of $2.62 billion, a P/E ratio of 885.72 and a beta of 0.20.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last posted its quarterly earnings data on Tuesday, July 29th. The company reported $0.23 EPS for the quarter, topping analysts’ consensus estimates of $0.18 by $0.05. Kiniksa Pharmaceuticals International had a net margin of 0.90% and a return on equity of 1.05%. The firm had revenue of $156.80 million during the quarter, compared to analyst estimates of $145.21 million. Kiniksa Pharmaceuticals International has set its FY 2025 guidance at EPS. On average, analysts expect that Kiniksa Pharmaceuticals International, plc will post -0.55 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on KNSA shares. Wedbush reaffirmed an “outperform” rating and set a $36.00 target price on shares of Kiniksa Pharmaceuticals International in a report on Monday, July 21st. Wall Street Zen upgraded Kiniksa Pharmaceuticals International from a “buy” rating to a “strong-buy” rating in a research note on Sunday, September 7th. Jefferies Financial Group raised their target price on Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the company a “buy” rating in a research note on Tuesday, July 29th. Finally, Wells Fargo & Company boosted their price target on shares of Kiniksa Pharmaceuticals International from $30.00 to $42.00 and gave the company an “overweight” rating in a report on Wednesday, July 9th. Six analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, Kiniksa Pharmaceuticals International currently has an average rating of “Buy” and a consensus target price of $41.17.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.